Semaglutide Tied to 50% Lower Risk for Epilepsy in Diabetes
The GLP-1 RA, semaglutide, significantly reduces epilepsy risk in diabetes, and this protective signal is driven by pathways unrelated to improvements in A1c or body weight. Medscape Medical News
PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence
Pfizer PFE announced that it is in-licensing exclusive global rights to develop, manufacture and commercialize YP05002, an oral small molecule GLP-1 receptor agonist (GLP-1 RA) from YaoPharma, a subsidiary of China’s leading drugmaker, Shanghai Fosun Pharmaceutical. YP05002 is currently being evaluated in phase I for treating obesity. Once-daily oral small molecule GLP-1 RAs are believed to have the […]
GLP-1 Medications, Such as Ozempic, Zepbound, Show Little Effect on Cancer, Study Shows
WEDNESDAY, Dec. 10, 2025 — A new study suggests popular GLP-1 drugs, like Ozempic and Zepbound, may not lower cancer risk as some had hoped.
Researchers analyzed 48 randomized trials including 94,245 adults who were overweight, obese or had…
New Ozempic-alternative diabetes pill burns fat without muscle loss, study suggests
Scientists in Sweden have created a new pill designed to help the body burn fat and control blood sugar in a different way than popular GLP-1 drugs, like Ozempic. While injectable GLP-1s work by suppressing appetite, this new treatment boosts metabolism in the muscles. A study led by researchers at Karolinska Institutet and Stockholm University […]
GLP-1: Threat or opportunity for manufacturers?
GLP‐1 receptor agonists for treating obesity without diabetes: A systematic review and meta‐analysis of economic evaluations
Abstract Aim To pool the incremental net benefits (INBs) of using glucagon-like peptide-1 receptor agonists (GLP-1RAs) for treating obesity without diabetes. Materials and Methods PubMed, Embase, EconLit, CEA Registry, ProQuest Dissertation and Theses Global were searched from inception to April 2024. Cost-effectiveness studies were included if they reported economic outcomes of any GLP-1RAs in the […]
JCM, Vol. 14, Pages 8734: The Effect of Semaglutide on Pancreatic β-Cell Function in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis
JCM, Vol. 14, Pages 8734: The Effect of Semaglutide on Pancreatic β-Cell Function in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis Journal of Clinical Medicine doi: 10.3390/jcm14248734 Authors: Omar Abusedera Jana Sherif Malak Smida Salim Fredericks Background/Objectives: Type 2 diabetes mellitus (T2DM) is characterized by progressive β-cell dysfunction and insulin resistance. Glucagon-like […]
GLP-1 has changed the snack game: Here’s how to win it back
GLP-1 users are rewriting the rules of appetite, texture and indulgence. Tate & Lyle’s latest research shows exactly where producers are missing the moment.
Thirty-five cases of adverse reactions to Mounjaro reported in first month of availability
Boxes of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes [LILLY KOREA] Thirty-five cases of adverse reactions or serious side effects were reported in Korea within the first month of the release of Mounjaro (tirzepatide), a weight loss drug developed by Eli Lilly. According to data submitted by the Korea […]
Is Tirzepatide Easier on the Eyes Than GLP-1s?
Using tirzepatide is linked to lower risks of developing primary open-angle glaucoma and elevated eye pressure in patients with type 2 diabetes than using GLP-1 receptor agonists, a study finds. Medscape Medical News